Tremelimumab usage regimen

Tremelimumab/Tremelimumab is a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blocking human IgG2 monoclonal antibody. It is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution. It is packaged in single-dose vials and diluted for intravenous infusion.

Tremelimumab injection is a liquid that is injected into a vein within 60 minutes by a doctor or nurse in a hospital or medical institution. For the treatment of hepatocellular carcinoma, it is usually given as a single dose. For the treatment of non-small cell lung cancer, it is usually given every 3 weeks for 4 doses (cycles 1 to 4), followed by a single dose at week 16 (cycle 6). Tremelimumabis used in combination with durvalumab and chemotherapy. Treatment consists of up to 5 doses, but treatment may be permanently stopped if the cancer worsens or the patient experiences severe side effects. Serious or life-threatening reactions may occur during the infusion. Tell the doctor or nurse immediately if the patient develops any of the following symptoms during the infusion: chills, flushing, shaking, dizziness, shortness of breath, wheezing, fever, itching, rash, back or neck pain, or dizziness.

Tremelimumab/Tremelimumab is a new type of cancer immunotherapy drug. It has not yet been launched in China, so it cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug. It is understood that the US version of temsitumumab original drug sold overseas may cost more than more than 3,000 US dollars per box, and the specification is 300mg/50mL (20mg/mL). The price is still relatively expensive. At present, we are not aware of the production and release of generic drugs of temsitumumab. For specific overseas prices and drug details, please consult Yaode Medical Consultants.